is an unusual, non-neoplasticfi brous lesion that most often arises in the mandible and maxilla. CCRC of the temporal bone is exceedingly rare. To the best of our knowledge. only 17 cases have been previously reported in the internationa l medical literatu re. Although no case of metastasis has been reported, this malignancy can be locally aggressive, and it of ten recurs fo llowing incomplete excision. We report the case of a young woman with a very large CC RC ofthe right temporal bone. We discuss the clinical picture, differential diagnosis, histologic evaluation, appearance on computed tomography and magnetic resonance imaging, and treatm ent options. We also review the cases of temporal bone CCRC that have been reported in the literature so f ar.
Introduction
Th e term giant-cell reparati ve granuloma (GCRG) was introdu ced by Jaffe in 1953 to describe a lesion of the mandibl e and maxill a that occ urred followi ng a traum ainduced intraosseou s hemorrhage.I He also distinguished GCRG, which is not a true neoplasm , from giant-ce ll tumor. Since 1953, GCRG has been rep or ted in many other sites, inclu ding the axial ske leto n and long bones;' the hands and feet,' the facial bones," the cranial vault,' the (table) . Although GCRG of the tem poral bo ne has been purpor ted to be a reaction to cranial traum a,J. . I J. Ĩ its pathogenesis remain s unclear. J3.J 4 It ca n occur at any age , and there does not appear to be a clear ge nder pred ilection. 13 Reported sy mptoms include hearing loss, tinnitus, a palpable mass, pain , ver tigo , and facial weakness." Complete surgical exc ision is regarded as the treatment of cho ice.'>!' Cur ettage of the lesion is not sufficient. 13 . 14 Whenever co mplete rem oval is not possibl e, radi oth erapy sho uld be considered." :" Foll owin g co mplete excision, the prognosis is go od, and reported recurren ce rates have ranged from 10 to 15% in most studies .11. [16] [17] [18] In this article , we rep ort a new case of temporal bone GCR G, in which a large tum or infiltrated the sphenoid bo ne, infra temporal fossa, pterygoid fossa, ternp orornandib ularjoint, middl e crani al fossa, and tem poral lobe. To our knowledge , infiltra tio n of the temporal lob e by a temp oral bone GCRG has not been previou sly described in the literature.
Case report
A l7-year-old gir l came to the Department of Otorhinolaryngology-Head and Neck Surgery in October 1998 with a 2-month histor y of hearing loss in her right ea r. She repo rted no other sy mptom s, and she had no history of head or aco ustic traum a or ex posure to ototox ic age nts. Her family histor y was nega tive for hea ring loss.
Examination of the head and neck revealed that a mass was obstructing the right auditory ca nal and had almost co mpletely occl ude d the lumen. Pure-tone aud iometry 
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GIAN T-C ELL REPARATIV E G RANULOMA OF THE TEMPORAL BON E: A CAS E REPORT AND REVIEW O F THE LITERATURE revealed normal functio n in the right inner ea r and a 20 -dB air-bo ne gap at all frequencies tested . Se rum levels of calcium, alkalin e phosph atase, phosph oru s, and parathyroid horm on e were withi n norma l limit s. Computed tomography (CT) dem on strated a 4-c m osteo lytic lesion of the right temp oral bone and infratemporal fossa with intracr an ial bu t extradura l extensio n. Th e temporomandibu lar joint was not invo lved. On magnetic reson ance imaging (M RI), the lesion reflected low-in tensity sig nals on both T 1-and T2-weigh ted images, but there was so me stro ng enhance ment followi ng the ap plicatio n of gadolinium co ntras t.
Because of the co ntrast enha nce ment, a pre op erati ve embo liza tion of the lesion was per form ed. Intra operat ive rapid sec tion revealed a tum or of unclear dignit y. For that reason , the operation was aba ndo ned after the mastoid ectom y and withou t complete removal of the tumor. The defi nitive histology revealed that the tumo r was a GC RG. The patie nt was sched uled to undergo a complete removal of the lesion , bu t unfortunately she and her mo ther refused the recommend ed surge ry.
In Februa ry 200 I, the yo ung wo man returned to our institution . Sinc e her initial treatm ent , the tum or had grow n significa ntly and the patient was ex per iencing total right-sid ed se nso rineura l deafn ess, intermittent vertigo, tinnitus, faci al weak ness (Ho use -Brackmann gra de 1I-III), and paresthesia in the area of the right mandibul ar nerve.
CT and MRI showed a very large tumor in the rig ht temporal bon e that invol ved the sphenoid bone, infratemporal fossa, pterygoid fossa , tem porom andibul ar j oint , and middl e cran ial fossa wi th extension into the right temp oral lob e (figure I). Th ere were erosions of the labyrinth and the bony ca na l of the intern al carotid artery as we ll as destruct ion of the right coc hlea .
Th e lesion was resected via a co mbined pter ion al and infra temporal approach. Th e operatio n was performed in cooperation with the Department of Max illofacial Surgery and the Department of Ne uros urgery, and we were co ntinuo us ly assiste d by co mputer-navigation co ntro l (St ryker Le ibinger Nav iga tion System ; Freiburg, Ge rmany). Th e tum or had dam aged a large portion of the right temp oral bone. Th e intern al caro tid artery, the facial ner ve, and the mandibular nerve were enshea thed. During the opera tion, large portion s of the temp oral bone (incl uding the coc hlea and the labyrinth ) and the temporom andibul ar joint (incl udi ng the articular disk, masseter, and med ial pterygoid muscle), parts of the temporal muscle, the greater wing of the sphenoid, the adventitia of the interna l carotid artery, the maxillary artery , the ma ndib ular nerve, parts of the tempora l du ra, and a sma ll part of the ca uda l tem poral lobe had to be resected. By per forming such a rad ical operatio n, we.were able to rem ove all tumor tissue as well as a margin of grossly unin volved tissue. We were able to spare the facial ner ve, and we treated it wi th a nerve sti mulator at the co mpletion of surgery. We recon structed the dur a with fasc ia lata and temp oral mu scle. Finally, we used a titanium mesh to restore the
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• 02003. Abbott laboratories ' 03G-olO·8920-1 • AugusI2OO3 • PrintedinU.SA Pediatric Use: Safety and effec tiveness of c1arithromycinin pediatric patients under6 months of agehave not been established.The safetyof clarithromycin hasnotbeen studiedinMACpatientsunder the age0120months. Neonatal and juvenile animals tolerated clarithromycin in a manner similar to adult animals. Y ounganimals were slightly more intolerant to acute overdosage and tosubtle reductions inerythrocytes, platelets, and leukocyt es butwere less sensitive to toxicityinthe liver,kidney, thymus, andgenitalia.
GeriatricUse:Inasteady· state study inwhichhealthy elderlysubjectslage65to 81 years old) were given500mg every 12 hours. themaximum serum concentrations andareaunde rthe curves ofclarithromycin and14-0H c1a rithromycinwere increasedcomparedtothose achievedinhealthyyoungadults.Thesechanges in pharmacokinetics parallel known age-related decreases in renal function. In clinicaltrials, elderly pat ients didnothavean increased incidence ofadverse events when compared to younger patients. Dosage adjustment should be consideredinelderly patients withsevere renal impairment ADVERSE REACTIONS -The majority of side effectsobserved in clinical trials were of a mild and transient nature. Fewer than 3%of adult patients wit hout mycobacterial infections and fewer than 2% of pediatric patients without mycobacterial infections discontinued therapy because of drug-related side effe cts. Fewer tha n1%of adult pat ients taking BIAXIN XLtablets discontinued therapybecauseof drug·relatedside effects. The most frequently reported events in adults taking BI AXIN tablets (clari thromycin tablets, USPI were diarr hea 13%1. nausea 13%1 . ab normal taste 13%). dyspepsi a 1 1%). abdominal pain/discomfort1 1%1. and headache 11%1. In pediatri c patients. the most Irequently reported events were diarr hea 16%1. vomi ting16%), abdominal pain13%1. rash 13%1, andheadache1 1%). Mosl 01these events were describ ed as mildor moderateinseverity. Of the reported adverse events, only1%wasdescribed assevere.
Themost frequ ent lyreported eventsin adultstakingBIAXIN XLIClarithromycin extended-release tablet s) were diarrhea 1 6%1 , abnormal taste 1 1%1. and nause a 13%1. Mostoftheseevents were de scribedasmild ormoderateinsever ity. Ofthe reportedadve rse events, less thanl%were describedas severe.
In the acute exacerbat ion ofchronic bronchitis and acute maxilla rysinusitis studies overall gastrointestinal adverse events were reported bya similar proporti on of patients taking either BIAXIN tablets or BIAXINXLtablet s; however. patientstaking BI AXIN XLtabletsrep ortedsignificantlyless severe gastrointestinalsymptoms comparedto patients takingBIAXIN tablets. In addition. patients takingBIAXI NXLtabletshad significant ly fewerprematuredi sconti nuations for dru g-rel ated gastrointestinal or abnormal taste adverse events compared to BI AXI Ntablets.
In community-acquired pneumonia studies conducted in adult s comparing clari thromycinto erythromycin base or er{t hromycinstearate,therewere fewer adverseevent s involvingthe digestive system in clarithromycin·treated patients comp ared toerythromycin-treatedpatients113%vs31%; p<O.OIl . Twentypercent of eryt hromycin·treated pat ients discontinued therapy due to adverse events comparedto4%ofc1arithromycin-treated patients.
In 1\' 0'0 U.S. studies of acut e otitis media comparing c1arithromycin to amoxicillin/ potassium clavul anateinpediatri c pat ient s, therewerefeweradverse events involving the digestive system in clarithromycin-treated pat ient s compa red to amoxicill in/potassium clavelanate-treated patients 121%vs. 40%, p<O .OOI). One-thirdasmany clarithromycin-treated pat ients reporteddiarrhea as didamoxicillin/potassiumclavul anat e·treatedpatients.
Post-MarketingExperience:
All ergicreactions rangingfrom urt icariaandmild skineruptionstorare cases of anaphylaxis, Stevens-Johnson syndrome and toxic epidermal necrolysis have occurred. Other spontaneously reported adverse events include glossitis, stomati tis, oral monil iasis, anorexia, vomiting. pancreatitis. tongue discoloration, thrombocytopenia, leukopeni a. neutropenia, and dizziness. There have been reports oftoothdiscol orationinpatients treatedwithBIAXIN.Toothdiscoloration is usuallyreversible with professional dentalcleaning. There have beenisolated reports ofhearing loss, which is usually reversible, occurring chiefl y in elderly wom en. Report s of alterations of the sense ofsmell , usually in conjunctionwith taste perversion ortaste loss havealso beenreported.
Transient CNS events including anxiety, behavioral changes. confusional states, convulsions, depersonalization. disorientation, hallucinations, insomnia, manicbehavior , nightmares, psychosis, tinnitu s, tremor, andvert igo have been reported during post-ma rketing surveillance. Events usually resol ve wi th di scont inuationofthedrug.
Hepatic dysfunction, including inc reased liver enzymes, and hepatoc ellular and/or cholestatic hepatit is, with or without jaundice, has been infrequently report ed with clarithromycin. This hepatic dysfunction may be severe and is usually reversibl e. Inveryrare instances,hepatic failure with fatal outcome has been reported and generally has been associated with serious underlying disea ses and/orconcomitantmedi cations.
There have been rare reportsof hypoglycemia, some ofwhich have occurred in patient s takingoral hypoglycemicagent s orinsulin.
Therehavebeenpostmarketing reportsof BI AXINXLtabletsinthestool,many ofwhichhaveoccurredinpatientswithanat omic(i ncluding ileostomyorcolostomy)or functionalgastrointestinaldisorderswith shortened GI transit times. As with other macrolides, clarithromyc in has been associated wi th OT prolong ation and ventri cular arrhythmias, including ventricul ar tachycardia and torsad esde point es. ChangesinLaboratoryValues:Changes inlaboratory valueswi thpossibleclinical signific ancewere as follows: Pseudomembrano us colitis has been reported with nearl y all antibacterial agent s, including clarithromycin,and may range in severi tyfrom mild to life threatening. Therefore, it is important toconsiderthisdiagnosis inpatient s who presentwithdiarrheasubsequent totheadministration ofantibacterialagents.
Treatm entwithantibacteri alagents alters the normalflo raofthecolonandmay permit overgrowth of clostridia. Studies indicate that a toxin produ ced by Clostridiumdiff icileis a pr imarycauseof"antibiotic-associated col itis", Aher the diagnosi s of pseudome mbranous col itis has been establi shed. therapeutic measures should be ini tiated. Mild cases of pseudomembranous colitis usuallyrespondtodiscontinuationofthedrugalone. Inmoderatetosevere cases. considerationshould be given tomanagement withfluids andelectrolytes, protein suppl ement ation, and treatment with an antibacterial drug clinically effective against Clostridiumdilficilecolitis.
Forinformationabout warnings 01other drugs indicated incombination with BI AXIN, refer totheWARNINGSsection oftheir packageinserts. PRECAUTIONS -General: Clarithromycinisprincipally excretedvia theliver and kidney. Clarithromycin may be administered without dosage adju stme nt to patients with hepatic impairment and normal renal function. However, in the presence of severe renal im pai rment wit h or without coexisting hepat ic impairment, decreaseddosageorprolongeddosingintervals may be appropriate. Clarithromycin in combination with ranitidine bismuth citrate therapy is not recommended inpatient s withcreatinineclearance less than25 mVmin.
Clarithromycin incombination wit h ranltidine bismuth citrate should not be usedinpatients with a history ofacute porphyria.
Forinformationabout precautions ofother drugsindicatedincombination with BIAXIN. refer tothePRECAUTIONS sectionoftheir packageinserts. 
refrigeratethesuspension.
DrugInt eractions: Clarithromycin use in patientswho arereceivingtheophylline may be associated with an increase of serum theophylline concentrat ions.
Monitoring of serum theophylline concentrations should be considered for patient s receiving highdoses oftheophylline orwi th baseline concentrations in the upper therapeutic range. In1\' 0' 0 studiesinwhichtheophyll ine was administered with c1arithromycin (a theophylline sustained·release formulation was dosed at either 6.5 mg/kg or 11 mg/kg together with 150 or 500 mg ql1h c1arithromycinj, thesteady-state levels of Cmax, Cm in, andthe area under the serumconcentration time curve IAUC) oftheophylline increasedabout20%. Concomitant adm inistration of single doses of clarithromyci n and carbamazepine has beenshowntoresult in increasedplasma concentrations of carbamazepine, Bloodlevel monitoring ofcarbamazepine maybe considered.
Wh enclar ithromycin and terf enadinewere coadministered, plasma concentrations ofthe active aci dmetabolit e ofterfenadine werethreefoldhigher, on average. than the valuesobservedwhen terfenadine was administered alone. The pharmacokinetics ofclarit hromycin and the 14-hydroxy-clarithromycinwere not signilicantly affected by coadministration of terfenadine once c1arithromycin reachedsteady·state conditions. Concomitant administrationof clarithromycin withtert enadineiscontraindicated.ISeeCONTRAINOICATIONS.)
Clari thromycin500mg every 8hourswas givenincombination withomeprazole 40 mgdailytohealthy ad ult subjects. Thesteadv-stateplasma concentrationsof omeprazole wereincreased(Cm ax, AUCO-24. and Ttnincreases of30%, 89%, and 34%. respectivel y). by the concomitant administration of clarith romycin. The mean24·hourgastric pHvaluewas 5.2whenomeprazolewasadministeredalone and5.7when co-administeredwithclarithromycin.
Co-administration of c1arithromycin wit h ranitidine bismuth citrate resulted in increased pl asma ranitidine concentrations 157%), increased plasma bismuth trough conce ntrations (48%), and increased 14-hydroxy·clar ithromycin plasma concentrations 131%1. These effects are clinicall yinsignificanl Simultaneous oral administrat ion of BIAXIN tablets and zidovudine to HIVinfectedadult patients resultedindecreased steady-state zidovudine concentrations. When 500 mg ofc1arith romycin were administered1\ ',icedaily, steady-state zidovudine AUC was reducedby amean of 11%I n~41 . Individual values ranged from a decrease of 34% to an increase of 14%. Based on limited dat a in 24 patients, whe n BIAXINtablets were administered 1\' 0' 0 to four hours prior to oral zidovudine, the steadv-state zidovudine Cmal was increased by approximatelyH old. whereasthe AUC wasunaffected.
Simultan eousadministrationofBI AXINtabletsanddidanosineto11HIV-inlect· ed adul t patients resulted in no statist icall y significant change in didanosine pharma cokinetics. Concomit. ant ad. ministration of fluconazole 200mg daily and clarithromycin 500 mg 1\ 'lIce dally to 21 healthy volunte ers led to increases in the mea n Sponta neous reports in the post-marketing per iodsuggest that concomitant administration ofc1arithromycinandoral anticoagulants may pote ntiate theeffects oftheoral anticoagulants. Prothrombintimes shouldbecarefully monitoredwhile pat ients arereceivingclarithromycinand oral ant icoagul ants simultaneously.
Elevated digoxinserum concentrat ions in patients receiving c1arithromycin and digoxin concomitantly have also been reported in post-marketinq surveill ance. Some pat ient s haveshown cl inicalsigns consistent withdigoxintoxic ity. includi ng potentiallyfatal arrhythmias. Serum digoxin concentrations should be carefully monitored whilepatientsarereceivingdigoxinandclarit hromycinsimultaneously.
Eryt hromycinand clarithromycinaresubstrates andinhibi tors ofthe3A isoform subfamily of the cytochrome P450 enzyme systemICYP3A). Coadminstration of erythromycinorc1arithromycin and a drug primarily metabolized byCYP3A may beassociated withelevations in drug concentrations that could increase or prolong boththetherapeutic and adverse effects ofthe concomitant drug. Dosage adjustments may be considered. and when possible. serum concentrations of drugs primarily metabolized byCYP3A should bemonitored closely in patients concurrentlyreceivingclarithromycin or erythromyc in.
The following are examplesof some clinically sign ificant C YP3A based drug interactions. Interactions withother drugs metabolized bythe CY P3Aisoform are also possible. Increasedserum concentrat ions ofcarbamazepine and theactive acidmetaboliteofterfenad ine wereobserved inclinicaltri alswithc1a rithromycin.
The following CYP3A based drug interact ions have been observed with erythromycinproducts and/orwithclarithromycin in postm arketingexperience: In addition. a Bacterial Reverse·MutationTest lAmes Test) has beenperf ormed onclarithromycinmetabolites with negative results.
Fertility an d reprod uction studies have sh own that daily doses of up to 160 mg/kg/day 11. 3 times the recommend ed maximum human dose based on mg/m2l to male andfema lerats caused noadverse effectsonthe estrous cycle, fertility, parturition, ornumberand viabilityofoffsp ring. Pl asmalevel s inratsaft er ISO mg/kg/daywere1times thehumanserum levels.
In the 150 mglkg/day monkeystudies. pl asma levels were3 times the human serum levels. When given ora llyat 150 mglkg/day 11.4timestherecomm end ed maximum huma n dose based on mg/m2). clarithromycin wasshownto produce embryonic loss in monkeys. This effect has been attributed to markedmaternal toxicity of thedrugat thishigh dose.
Inrabbits. inutero fetalloss occurredatanintravenous doseof33mg/m2,which is 17 times less thanthe maximum proposedhumanoraldaily dose of618mg/m2. lonq-term studies in ani mals have not been performed to evaluate the carcinogenic potential ofclari thromycin.
Pregnancy:TeratogenicEffects. PregnancyCategoryC.
Fourteratogenicitystudiesinrats lthreewith oraldoses andonewithintravenous
doses upto 160mg/k g/ day administeredduringtheperiodofmajor organogenesis)and twoinrabbits at oral doses upto 115mg/kg/daylapproximately 1times the recommended maximumhuman dose based onmg/m2) orintrave nous doses of30 mg/kg/day administereddur inggestationdays 6to18failed todemonstrate anyteratogenicity fro mc1arithromycin. Two additional oral studiesin a different rat strainatsimilar doses and similar conditions demonstrated a low incidence of cardiovascular anomaliesat doses of 150 mg/kglday administe red duringgesta-tiondays6to15.Plasmalevels aher 150 mglkg/daywere1timesthe humanserum levels. Fourstudies inmice revealedavariable incidenceofcleftpalat e following oral doses of1000 mglkg/day1 1and 4times the recommendedmaximumhuman dose basedonmg/m2•respectively)duringgestationdays6to15.Clehpalatewas al soseen at 500mg/kglday.The1000 mg/kg/day exposure resultedinplasmalevel s11t imesthehuman serum levels. Inmonkeys. anoral dose of10mglkg/day lan approximate equidose of the recommended maximum human dose based on mg/m2) producedfetal growth retardat ion at plasma levels that were 2times the human serum levels.
There are no adequate and well -controlled studies in pregnant wome n. Clarithromycin should be used during pregnancy onl y if the potential benefit just ifiesthepotentialrisktothefetus.ISeeWARNINGS.)
NursingMothers: Itisnot knownwhetherc1arithromyc inis excretedinhum anmil k. Becausemany drugs areexc retedinhumanmilk,cautionshouldbeexercised when cl arithromycin isadminist ered toa nursingwoman.Itis known thatclarithromycin is excreted inthemil k oflactaling ani ma lsand that ot her drugs ofthisclass are excretedinhuma nmil k. Preweanedrats. exposedindirectlyviaconsumption ofmilk from dams trea ledwith ISOmglkg/day for3 weeks. werenot adversely affected despitedata indicatinghigherdruglevels inmilk than inplasma. T he excised lesion was ligh t brow n and had a soft, friable consistency. Histologically, there was a fibro plastic pro liferation with osteoclast-like po lynuclear gia nt cells, new ly for med osteoid trabeculae, lymphocytic infiltrates, macroph ages, and hem osiderin deposits (figure 2, A). Immunoh istochem ical studies yie lded positive vimentin staining of the fibrob lastic spindle cells . The osteoclastic origin of the giant ce lls was co nfirmed by positive staining with tartrate-resistant acid phosph atase (fig ure 2, B ) in combination wit h negat ive reacti ons for S 100 and CD Ia; these findi ngs also excl uded Langerhans' -cell histiocytosis.
Corona l MRI with gado lini um co ntrast 2 weeks following surgery revealed no signs of res idua l tumor ( figure 3) . Postoperatively, the patient ex hibited a profound weakness of the righ t facial nerve (Ho use -Brackmann grade V), but she gradually experienced a complete recovery within 6 mon ths. Her vertigo gradually reso lved over 4 week s. During the first 12 months postoperatively, she complained that her powers of concentration had diminished. She also reported a permanent numbness in the area of the right mand ibular nerve and total right-sided deafness.
In view of the size of the tumor and the invo lvement of bo ne, muscle, connective tissue, the mandibul ar j oint, the dura mate r, and the brai n, postoperative radiat ion was recommend ed by the Dep artment of Radiation Th erapy, but the patient decl ined . Fur ther treatm ent of the altered occ lusio n of her mouth was ad ministe red in the Dep art-Volume 82, Number 12 ment of Maxi llofacial Surgery. The most recent MRI was co nducted in March 2003, and there was no sign of recurrence.
Discussion
GC RG is a rare, benign , gran ulomato us lesion.'? W hen it does occ ur, it most often arises in the mand ible and maxill a; it ca n also invol ve any other bone in the jaw, check, and ext rag nathic region." Including our patient , only 18 cases of GCRG of the temporal bone have been repor ted in the interna tiona l med ical literature (table) . Th is gro up inclu des 6 fema les and 12 males, age d 4 mo nths to 72 years (mea n: 30 .2 yr). Although different authors have reported that GCRG of the jaw has a predilection for females, 1. 17.2 1.22 such does not appear to be the case for GCRG of the temporal bone. Eve n so, becau se of the small number of cases that have been repo rted, it is not possib le to spec ulate whet her there is a true gen der predilection for temporal bo ne GCRG.
Among the 13 cases in which the authors specified the length of follow-up, monitori ng time ranged fro m 10 months to 15 years (mean: 3.8 yr). Three reports contained no information on the length of follow-up, and two contained no information on fo llow-up at all. Of the 16 patients who were followed up after treat ment, on ly two (12 .5%) experienced a recurrence.
Symptoms. The reported sympto ms of GCRG of the temporal bone incl ude hearing loss, tinn itus, a palpabl e mass, pai n, vertigo, and facia l wea kness. Condu ct ive hearing loss was the most co mmon sy mpto m, occ urring in 12 of the 18 pati ent s (66. 7%). Tinn itus and a palpable 93 3 BOED EKER, KAYS ER, RIDDER, MA IER, SC HIPPER Etiology. The pathogenesis of GCRG is still controversial. 13.14 Ja ffe wrote th at the lesion represent s a hyp erpl astic , reparative reaction to an intraosseou s hemorrhage indu ced by trauma. 1 Many authors still share this opinion . 2 . 12 It must be menti oned, however , that there was no history of head trauma or previous surge ry in 9 of the 18 cases of temp or al bon e GCRG. In another 5 cases, the authors did not rep ort whether there had been any trau ma. In fact, only 4 cases involved so me prev ious trau ma to the head . In one of those reports, the authors cla imed that the lesion had occ urred secondary to blu nt trau ma inflicted by a cricket bat.' ? However, the fact that this traum a had occ urre d only 6 weeks before the patien t so ught treatm ent for his tum or makes it most unl ikely that the 3 x 2 x 1.5-cm GCRG had actu all y been ca used by that particul ar trauma. Oth er ca uses that have been proposed include infecti on s,11developm ent al anoma lies ,'? and hormonal influ enc es," but no single theory has gai ned wide acceptance." Differential diagnosis. Th e dia gn osis of GCRG is based on the combination of clini cal inform ation , rad iologic dat a, histopathologic charac teristics, and response 934 to treatm en t. 13 GCRG must be differentia ted fro m the brown tumor of hyp erparath yroidism , ane urys ma l bone cys t, chondroblasto rna, fibro us dyspl asia, cherubis m, osteosarcom a, and tru e giant-ce ll tumor. 12-14.1 8
Brown tumor of hyp erp arathyroidism. Th e histologic appearance of the bro wn tum or of hyperparath yroidi sm is often ind istinguisha ble fro m GCRG. 10.1 3.14 St ill, the differentiation between the two ca n be made witho ut difficulty by measurin g serum calcium, phosph oru s, and alkaline ph osph atase level s? as well as phosph ate clearance and levels of parathyroid horm one and urin e hydr oxypro tein ."
Ane urysmal bone cys t. Aneurysm al bon e cyst is another non-neoplastic , reparative process with a giant-cell compo nent.13.24 A cy stic blow-out of the bon e is a typical findin g on plain x-ray." On MRI , aneu rysmal bon e cyst is usu ally not homogeneou s and is charac terized by a high signal intensity.P:':' Histolog icall y, it is cha racterized by thin-walled, blood-containin g cystic cavities that are lined with flat fibro blastic ce lls and bony g iant ce lls .24Ane urysmal bone cys t of the temporal bone is exceed ing ly rare, as only 10cases have been reported in the liter atu re."
Cho ndro blasto ma . Cho ndro blastoma of the head and neck is mos t often located in the temporal bone." It is character ized by local recu rrence and metastasis, and it sho uld be co nside red cl inica lly to be a malign an t tumor. " Its important histop ath ol ogic features are foc al chondroi d di fferenti ation, interc ellular ca lcifica tion, and ep itheliumlike ce lls in nodul es and ribb ons with sca tte red, mul tinucl eat ed g iant ce lls and granular hem osid erin pigment s.20.25.26 On CT , ch ond robl astoma app ears as a highdensit y mass with mild contrast enhancement."
Fibro us dyspla sia . Th e typical histopathologic features of fibrou s dysplasia are the presen ce of ost eolysis, immatur e bon e trab eculae, and fibro-osseou s tis sue in the affected part of the bon e." Its signal inten sity is typi cally low on both TI-and T2-w eight ed MRI Y Few er than 80 cases of temporal bone fibrou s dysplasia have been report ed in the internation al medi cal literature."
Che rubistn. Ch erubism is a rare, beni gn , aut osom aldominant inheri ted condition character ized by cys tic proliferati on of the ma ndible and maxilla in childh ood.P:" Histologicall y, it fea tures prol iferating vasc ular fibro us tissue with osteoclas tic, mul tinucleated giantcells." Radiolog icall y, there is a specific finding of bilateral, multilocul ar cystic ex pa nsion of the j aws." Ch erubism does not occur in the temporal bone.
Osteosarco ma. Th ere might be a large, beni gn gia ntce ll co mponent to os teosarco ma, but the prese nce of atypia of the mononucl eat ed ce lls is a use ful criter ion in making the differenti al d iagn osis between it and GCRG. 20 Giant -cell tumor. Gi ant-cell tum or is ofte n di fficult to di stin gui sh fro m GCRG Y ·14.20 Prior to Jaffe ' s rep ort in 1953 ,1all giant-ce ll lesion s were design ated as giant-cell tumors, " GCRG has oft en been misdiagno sed as g iant-
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Let us give you all tbe details. ce ll tum or ,' :' :" es pecially during the yea rs before the firs t reported ca se of temporal bone GC RG by Hir schI and Katz in 1974. 11 T rue gia nt-cell tumor is a real neoplasm , and it acco unt s for 3 to 7% of all pr ima ry bo ne tumors." In most ca ses, it occ urs at the ends of lon g bc nes.P-"
Imaging Solutions
Bertoni et al reviewed 2,046 cases of g ian t-ce ll tumo r and fo und that only one had occ urred in the tem poral bon e." T he primary difference between gia nt-ce ll tum or and GCRG is the progn osis." Gi ant-ce ll tum or is reported to have a higher inc ide nce of recurren ce than GCR G ; repo rted recurren ce rates of giant-cell tum or of the lon g bon es range between 45 and 62 %.14Giant-cell tumor may undergo mali gn ant trnn sformation ." :" and metastatic sp read, usuall y to the lung, occ urs in I to 6% of cases of gia nt-cell tum or of the ex tremit ies. IV ! In gia nt-ce ll tum or of the cra nio fac ial bo nes , only one case of lymph nod e metastasis and no case o f pulmo nary metastasis has been noted."
On rad iologic evaluatio n, giant-cell tum or and GCR G are indistingui sh abl e.!' :':' O n CT, both usu all y appear as a non speci fic lytic lesion .1. 1.14 On MRI, most lesion s reflect a low sig na l int en sity on T 1-and T 2-w eight ed imaging. 13 . 14 Both tum or s en ha nce with ga do linium contrast ; the degree of enha nce me nt ran ges from slight" to strong . 13 Becau se of the non specific nature of the radio logic findings , the d ifferent iat ion bet ween giant-ce ll tum or and GCRG mu st be mad e histolog icall y. Giant-cell tum or origi nates in the co nnec tive tissue ofbone marrow, whereas GC RG arises from per iosteal co nnec tive tissue.':' Several histopathologic differences bet ween the two lesion s have been descr ibed in the literature. GC RG has been rep orted to co ntai n fewer mul tinucl eated gia nt ce lls than has giantce ll tum or. 14T he g iant ce lls in giant-cell tum or tend to be more eve nly d istr ibu ted and havea more un iform appearance .": ": " GC RG is associated with a grea ter degree of os teo id for mation, hem orrhage, hemosid er in depositi on, and inflamma tion.' ! Th e spindling qu alit y of the ce lls that encircle the giant ce lls has been described as a con sistent feat ure o f GC RG .4.I X .20 In g iant-ce ll tum or, typ ical findings are foci of nec rosis and the prese nce of mark ed mit oti c activity . '! Th ere may be areas of a GC RG lesion that ca nno t be histologicall y di fferenti ated from giant-ce ll tum or." Ung et al recommended maintain ing the curre nt nom encl ature of giant-cell tum or and GCRG whe never a clear distin ction bet ween the lesion s ca n be made histol ogicall y.14 In borderlin e cases, however, they preferred the term gianteel/ lesion, wh ich ca n be fur ther clas sified as aggressive or nonaggressive on the basis of symptoms. ':' However , we agre e wi th Bert oni et al that it is imp ortant to make every effort to separate gia nt-cell tu mor of the skull fro m GCRG becau se the prognosis of gia nt-cell tumo r is ge nera lly much wo rse ." Berto ni et al described 15 cases o f giant-ce ll tum or of various sk ull bon es; 3 o f those patie nts 93 6 died of giant-ce ll tllI110r. 20 T o the best of our know ledge , there is not a sing le reported ca se of death ca used by GC RG .
Treatment. Co mp le te surgical excision is the therap y of choic e for GC RG Y ·14So me autho rs have claimed that cure ttage is su fficient for treatment.' :'>" However, Aucl ai r et al noted that the recu rrence rate following simple cure ttage of GC RG was 50 %, co mpared with a rec urrence rate of only 10% fo llowi ng co mplete surgical exci sion .. 11 For large tumo rs, preoperative superse lec tive intravascular embolization has bee n advocated." Unl ike gia nt-cell tum or, GCRG does not undergo mali gn ant tran sform ation , and the re is not a sing le docum ent ed ca se of GCRG metastasis."
Co mplete exc ision of gia nt-ce ll tum or s of the long bo nes ca n usuall y be perform ed withou t major difficult y. However, the sk ull base, wit h its large number of vita l struc tures, pro vid es a significa nt cha lle nge to co mplete surgical rernoval.!' In cases where co mplete resectio n is not poss ible, postop erati ve radi ati on has bee n ad voca red. ':' :" Of the 18 pati ent s who have had GC RG of the temporal bone , 3 und erwent radia tio n therap y-2 after a co mp lete resection and I after an inco mplete resecti on . Th e size of the radi ati on doses varied greatly-from 600 and 5,000 cGy . Es pecially in yo ung patient s, rad iation therap y for thi s primarily beni gn lesion should be perfor med only whe n co mplete resectio n is not possibl e or whe n the tu mo r has infiltrated many di fferent structures , as hap pen ed in our pa tie nt. Keep in mind that an y radiation therapy car ries the potenti al risk of sarco matous tran sformati on in the decad es to co me ." O n the other hand , patients with g iant-ce ll tum or o f the temporal bone sho uld always und ergo radia tio n fo llow ing resectio n in light of the high risk of rec urre nce ."
De Lange et aF 2and Pogrel et aP 3rep ort ed a tot al of six patients with GC RG of the jaw who ex perienced a co mplete remission after they we re treated with calci tonin. Anti-inflamma tory dru gs may playa future ro le in the treatment of GCRG, but more da ta are need ed , es pecially lon g-term results, before ca lcitonin treatm en t ca n be regarde d as an ade qua te alterna tive to surgery .':' Taking you where you want to goo OTOLARYNGOLOGY Universal Health Services is on e of the nat ion' s largest health carc managemen t compa nies. \Vlc ow n and operate acu te care facilities across the country, and support these organizations by providing professional services to their affiliated physician groups. Because we represent a wide range of practice oppo rtunities throu ghout rhe co untry, we can help get y Oli to wherever it is y Oli wa nt to go.
Were current ly assisting in the search for board-certified Otolaryngologists to joi n estab lished private practices in th e areas listed on the left. 
